Broker Tips
Broker tips: ASOS, Dechra Pharmaceuticals, Mediclinic
ASOS can quadruple revenue in the next decade, Goldman Sachs analysts said as the investment bank increased its share price target for the online fashion retailer.
UBS downgrades Mediclinic after price recovers from low
UBS downgraded Mediclinic to 'neutral' from 'buy' as the risk-reward ratio "now looks more balanced" and the stock recovered from its low in November.
Tuesday broker round-up
Dechra Pharmatheuticals: Jefferies upgrades to buy with a target price of 2,631p.
Goldman Sachs increases share price target for ASOS
ASOS can quadruple revenue in the next decade, Goldman Sachs analysts said as the investment bank increased its share price target for the online fashion retailer.
Jefferies upgrades Dechra Pharmaceuticals after Dutch acquisitions
Jefferies upgraded its stance on veterinary pharmaceutical company Dechra Pharmaceuticals to ‘buy’ from ‘hold’ and lifted the price target to 2,322p from 2,221p following the group’s acquisition of Dutch firms AST Farma and Le Vet.